Effect of immunosuppressive therapy on patients with inflammatory bowel diseases and hepatitis B or C virus infection

Journal of Viral Hepatitis

Volumn 20, Issue 3, 2013, Pages 200-208

  Morisco, F ^a   Castiglione, F ^a   Rispo, A ^a   Stroffolini, T ^b   Sansone, S ^a   Vitale, R ^a   Guarino, M ^a   Biancone, L ^c   Caruso, A ^d   D'Inca, R ^d   Marmo, R ^e   Orlando, A ^f   Riegler, G ^g   Donnarumma, L ^a   Camera, S ^a   Zorzi, F ^c   Renna, S ^f   Bove, V ^g   Tontini, G ^h   Vecchi, M ^h   Caporaso, N ^a   more..

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

^d UNIVERSITY OF PADOVA   (Italy)

^e Gastroenterology Unit   (Italy)

^f VILLA SOFIA CERVELLO HOSPITAL   (Italy)

^g SECOND UNIVERSITY OF NAPLES   (Italy)

^h UNIVERSITY OF MILAN   (Italy)

Author keywords

antivirals; biological agents; HBV reactivation; HCV reactivation; prophylaxis

Indexed keywords

ADALIMUMAB; ALANINE AMINOTRANSFERASE; AZATHIOPRINE; CYCLOSPORIN; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; HEPATITIS C ANTIBODY; INFLIXIMAB; LAMIVUDINE; METHOTREXATE; STEROID;

ADOLESCENT; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CONTROLLED STUDY; CROHN DISEASE; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION PREVENTION; ITALY; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OBSERVATIONAL STUDY; PATIENT REFERRAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT DURATION; ULCERATIVE COLITIS; VIRUS LOAD; VIRUS REACTIVATION;

ADOLESCENT; ADULT; AGED; ALANINE TRANSAMINASE; FEMALE; HEPACIVIRUS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; ITALY; MALE; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; RETROSPECTIVE STUDIES; TERTIARY CARE CENTERS; VIRAL LOAD; VIRUS ACTIVATION; YOUNG ADULT;

EID: 84873422006     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2012.01643.x     Document Type: Article

References (38)

1. Dignass A, Van Assche G, Lindsay JO, et al,. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: current management. J Crohn's Colitis 2010; 4: 28-62.
2. Travis S, Stange EF, Lemann M, et al,. European evidence-based Consensus on the management of ulcerative colitis: current management. J Crohn's Colitis 2008; 2: 24-62.
3. Caprilli R, Angelucci E, Cocco A, et al,. Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement. Digest Liver Dis 2005; 37: 407-417.
4. Kamdar KY, Rooney CM, Heslop HE,. Posttransplant lymphoproliferative disease following liver transplantation. Curr Opin Organ Transplant 2011; 16: 274-280.
5. Beaugerie L, Brousse N, Bouvier AM, et al,. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet 2009; 374: 1617-1625.
6. Rahier JF, Ben-Horin S, Chowers Y, et al,. European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohn's Colitis 2009; 3: 47-91.
7. Hanauer SB, Feagan BG, Lichtenstein GR, et al,. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359: 1541-1549.
8. Rutgeerts P, Sandborn WJ, Feagan BG, et al,. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353: 2462-2476.
9. Colombel JF, Sandborn WJ, Rutgeerts P, et al,. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007; 132: 52-65.
10. Millonig G, Kern M, Ludwiczek O, Nachbaur K, Vogel W,. Subfulminant hepatitis B after infliximab in Crohn's disease: need for HBV-screening? World J Gastroenterol 2006; 12: 974-976.
11. Ueno Y, Tanaka S, Shimamoto M, et al,. Infliximab therapy for Crohn's disease in a patient with chronic hepatitis B. Digest Liver Dis 2005; 50: 163-166.
12. Madonia S, Orlando A, Scimeca D, Olivo M, Rossi F, Cottone M,. Occult hepatitis B and infliximab induced HBV reactivation. Inflamm Bowel Dis 2007; 13: 508-509.
13. del Valle Garcia-Sanchez M, Gomez-Camacho F, Poyato-Gonzalez A, Iglesias-Flores EM, de Dios-Vega JF, Sancho-Zapatero R,. Infliximab therapy in a patient with Crohn's disease and chronic hepatitis B virus infection. Inflamm Bowel Dis 2004; 10: 701-702.
14. Colbert C, Chavarria A, Berkelhammer C,. Fulminant hepatic failure in chronic hepatitis B on withdrawal of corticosteroids. Azathioprine and infliximab for Crohn's disease. Inflamm Bowel Dis 2007; 13: 1453-1454.
15. Esteve M, Loras C, Gonzalez-Huix F,. Lamivudine resistance and exacerbation of hepatitis B in infliximab-treated Crohn's disease patient. Inflamm Bowel Dis 2007; 13: 1450-1451.
16. Ojiro K, Naganuma M, Ebinuma H, et al,. Reactivation of hepatitis B in a patient with Crohn's disease treated using infliximab. J Gastroenterol 2008; 43: 397-401.
17. Esteve M, Saro C, González-Huix F, Suarez F, Forné M, Viver JM,. Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis. Gut 2004; 53: 1363-1365.
18. Loras C, Gisbert JP, Mínguez M, et al,. Liver dysfunction related to hepatitis B and C in patients with inflammatory bowel disease treated with immunosuppressive therapy. Gut 2010; 59: 1340-1346.
19. Zeitz J, Mullhaupt B, Fruehauf H, Rogler G, Vavricka SR,. Hepatic failure due to hepatitis B reactivation in a patient with ulcerative colitis treated with prednisone. Hepatology 2009; 50: 653-654.
20. Sacco R, Bertini M, Bresci G, Romano A, Altomare E, Capria A,. Entecavir for hepatitis B virus flare treatment in patients with Crohn's disease. Hepatogastroenterology 2010; 57 242-245.
21. Markovic S, Drozina G, Vovk M, Fidler-Jenko M,. Reactivation of hepatitis B but not hepatitis C in patients with malignant lymphoma and immunosuppressive therapy. A prospective study in 305 patients. Hepatogastroenterology 1999; 46: 2925-2930.
22. Zein NN, Etanercept Study Group. Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis c virus infection: a phase 2 randomized, double-blind, placebo-controlled study. Journal of hepatol 2005; 42: 315-322.
23. Lok AS, McMahon BJ,. Chronic hepatitis B. Hepatology 2007; 45: 507-539.
24. Marzano A, Angelucci E, Andreone P, et al,. Italian Association for the Study of the Liver. Prophylaxis and treatment of hepatitis B in immunocompromised patients. Dig Liver Dis 2007; 39: 397-408.
25. Yeo W, Chan PK, Hui P, et al,. Hepatitis B virus reactivation in breast cancer patients receiving cytotoxic chemotherapy: a prospective study. J Med Virol 2003; 70: 553-561.
26. Law JK, Ho JK, Hoskins PJ, Erb SR, Steinbrecher UP, Yoshida EM,. Fatal reactivation of hepatitis B postchemotherapy for lymphoma in a hepatitis B surface antigen-negative, hepatitis B core antibody-positive patient: potential implications for future prophylaxis recommendations. Leuk Lymphoma 2005; 46: 1085-1089.
27. Lok AS, Liang RH, Chiu EK, Wong KL, Chan TK, Todd D,. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology 1991; 100: 182-188.
28. Morisco F, Castiglione F, Rispo A, et al,. Hepatitis B virus infection and immunosuppressive therapy in patients with inflammatory bowel disease. Dig Liver Dis 2011; 43 (Suppl 1): S40-S48.
29. Chevaux JB, Nani A, Oussalah A, et al,. Prevalence of hepatitis B and C and risk factors for nonvaccination in inflammatory bowel disease patients in Northeast France. Inflamm Bowel Dis 2010; 16: 916-924.
30. Loras C, Saro C, Gonzalez-Huix F, et al,. Prevalence and factors related to hepatitis B and C in inflammatory bowel disease patients in Spain: a nationwide, multicenter study. Am J Gastroenterol 2009; 104: 57-63.
31. Biancone L, Pavia M, Del Vecchio Blanco G, et al,. Hepatitis B and C virus infection in Crohn's disease. Inflamm Bowel Dis 2001; 7: 287-294.
32. Papa A, Felice C, Marzo M, et al,. Prevalence and natural history of hepatitis B and C virus infection in a large cohort of patients affected by inflammatory bowel disease in treatment with anti-TNFa agents. J Crohns Colitis 2012 Mar 29. [Epub ahead of print].
33. Orlando A, Armuzzi A, Papi C, et al,. The Italian Society of Gastroenterology (SIGE) and the Italian Group for the study of Inflammatory Bowel Disease (IG-IBD) Clinical Practice Guidelines: The use of tumor necrosis factor-alpha antagonist therapy in inflammatory bowel disease. Dig Liver Dis 2011; 43: 1-20.
34. Kohrt HE, Ouyang DL, Keeffe EB,. Antiviral prophylaxis for chemotherapy-induced reactivation of chronic hepatitis B virus infection. Clin Liver Dis 2007; 11: 965-991.
35. Zingarelli S, Frassi M, Bazzani C, Scarsi M, Puoti M, Airò P,. Use of tumor necrosis factor-alpha-blocking agents in hepatitis B virus-positive patients: reports of 3 cases and review of the literature. J Rheumatol 2009; 36: 1188-1194.
36. Papamichalis P, Alexiou A, Boulbou M, Dalekos GN, Rigopoulou EI,. Reactivation of resolved hepatitis B virus infection after immunosuppression: is it time to adopt pre-emptive therapy? Clin Res Hepatol Gastroenterol 2012; 36: 84-93.
37. Pei SN, Chen CH, Lee CM, Wang MC, Ma MC, Hu TH, Kuo CY,. Reactivation of hepatitis B virus following rituximab-based regimens: a serious complication in both HBsAg-positive and HBsAg-negative patients. Ann Hematol 2010; 89: 255-262.
38. Vento S, Cainelli F, Longhi MS,. Reactivation of replication of hepatitis B and C viruses after immunosuppressive therapy: an unresolved issue. Lancet Oncol 2002; 3: 333-340.